<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01605084</url>
  </required_header>
  <id_info>
    <org_study_id>AI424-493</org_study_id>
    <secondary_id>2011-006186-18</secondary_id>
    <nct_id>NCT01605084</nct_id>
  </id_info>
  <brief_title>Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone</brief_title>
  <acronym>SUPPRESS</acronym>
  <official_title>An Open-Label Phase 3B Study in HIV-Infected Individuals With Viremia on or After Their First-Line Non-Nucleoside Reverse Transcriptase Inhibitor or Integrase Inhibitor-Based Regimen and Starting a Second-Line Regimen Consisting of ATV/RTV or DRV/RTV With an Optimized NRTI Backbone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the proportion of subjects with HIV-1 RNA &lt; 50 c/mL
      at Week 48 in patients who failed their first line therapy containing a non-nucleoside
      reverse transcriptase inhibitor (NNRTI) or an integrase inhibitor
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Allocation: Randomization will be stratified

        -  ATV = Atazanavir

        -  DRV = Darunavir

        -  RTV = Ritonavir
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects with Human immunodeficiency virus 1 (HIV-1) Ribonucleic Acid (RNA) &lt; 50 c/mL</measure>
    <time_frame>At Week 48</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with HIV-1 RNA &lt; 50 c/mL</measure>
    <time_frame>At week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in CD4 cell count</measure>
    <time_frame>Baseline (Week 0) and at week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence rates of serious adverse event (SAEs) and adverse events (AEs) leading to discontinuation</measure>
    <time_frame>up to week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence rates of antiretroviral resistance measured by newly emergent genotypic substitutions and phenotypic resistance to study drugs for virologic failure</measure>
    <time_frame>up to week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with HIV-1 RNA &lt; 50 c/mL at Week 48 by baseline M184V presence or absence</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Arm 1: ATV/RTV 300/100 mg QD + optimized NRTI backbone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: DRV/RTV 800/100 mg QD + optimized NRTI backbone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atazanavir</intervention_name>
    <description>Capsule, Oral, 300 mg, Once daily (QD), 48 weeks</description>
    <arm_group_label>Arm 1: ATV/RTV 300/100 mg QD + optimized NRTI backbone</arm_group_label>
    <other_name>REYATAZ®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Darunavir</intervention_name>
    <description>Oral, Two 400 mg Tablets, Once daily (QD), 48 weeks</description>
    <arm_group_label>Arm 2: DRV/RTV 800/100 mg QD + optimized NRTI backbone</arm_group_label>
    <other_name>PREZISTA®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir</intervention_name>
    <description>Tablet, Oral, 100 mg, Once daily (QD), 48 weeks</description>
    <arm_group_label>Arm 1: ATV/RTV 300/100 mg QD + optimized NRTI backbone</arm_group_label>
    <arm_group_label>Arm 2: DRV/RTV 800/100 mg QD + optimized NRTI backbone</arm_group_label>
    <other_name>NORVIR®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Optimized NRTI backbone</intervention_name>
    <description>tablet/capsule, Noninvestigational products i.e. NRTI backbone will be administered according to their respective package inserts for 48 weeks
NRTI backbone are:
- Abacavir (300 mg), Tenofovir (300 mg), Didanosine (250 mg or 400 mg), Stavudine (30 mg or 40 mg), Emtricitabine (200 mg), Lamivudine (300 mg), Zidovudine (300 mg), EPZICOM® (600 mg Ziagen® + 300 mg Lamivudine), COMBIVIR® (150 mg Lamivudine + 300 mg Zidovudine)
The following NRTI combinations are prohibited in this study:
Didanosine + Stavudine
Zidovudine + Stavudine
Lamivudine + Emtricitabine</description>
    <arm_group_label>Arm 1: ATV/RTV 300/100 mg QD + optimized NRTI backbone</arm_group_label>
    <arm_group_label>Arm 2: DRV/RTV 800/100 mg QD + optimized NRTI backbone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed informed consent

          2. HIV-1 infected patients with viremia (VL ≥ 500/mL) on or after their first NNRTI or
             INI-based cART regimen and meeting one of the two criteria below:

               -  On 1st line Non-nucleoside reverse transcriptase inhibitor (NNRTI) or Integrase
                  inhibitor (INI)-based Combination antiretroviral therapy (cART) with HIV-1 RNA ≥
                  500 c/ML after being on the same therapy for at least 12 weeks

               -  Off 1st line NNRTI or INI-based Combination antiretroviral therapy (cART) for at
                  least 2 weeks after having been on antiviral therapy for at least 4 weeks and who
                  are non-compliant and off first line cART without a history of virologic failure
                  with resistance, with a : HIV-1 RNA ≥ 500 c/ML

          3. Fully sensitive genotype and phenotype report for Atazanavir/Ritonavir (clinical
             cut-off of 5.2) and Darunavir/Ritonavir (clinical cut-off ranging from 10 to 90)

          4. At least one NRTI other than Lamivudine (3TC) or emtricitabine (FTC) with full
             sensitivity (one &quot;active&quot; NRTI) by genotype and phenotype, ie, PhenoSense Genotype
             (GT), report must provide a &quot;sensitive&quot; net assessment of susceptibility. An NRTI or
             PI (reported with or without ritonavir) with a &quot;partially sensitive&quot; net assessment
             will not be considered &quot;fully sensitive&quot;

        4. Mentally able to participate in the study 5. Men and women ≥ 18 years old

          -  Women of child bearing potential who engage in vaginal intercourse and who are not
             clinically sterilized must use highly effective methods of birth control during the
             study

        Exclusion Criteria:

          1. Screening HIV genotype showing presence at baseline of any of the following Protease
             inhibitor (PI) Mutation Patterns associated with genotypic resistance to Atazanavir
             sulfate/ Ritonavir or Darunavir/Ritonavir will lead to exclusion:

               1. Subjects with any darunavir associated mutations* at baseline (*V11I, V32I, L33F,
                  I47V, I50V, I54L, I54M, T74P, L76V, I84V and L89V)

               2. Subjects with a major mutation to Atazanavir sulfate consisting of N88S

               3. Subjects with more than 3 of any of the following Atazanavir sulfate related
                  mutations:D30N, M36I/V, M46I/L/T, I54V/L/T/M/A, A71V/T/I/G, G73S/A/C/T, V77I,
                  V82A/F/T/S/I, I84V/A, N88D or L90M

          2. Subjects with &lt; 1 fully active NRTI on PhenoSense report, other than lamivudine and
             emtricitabine

          3. Diagnosed with active tuberculosis

          4. Chronic hepatitis B infection

          5. Hepatitis C-positive patients who are not clinically stable or need treatment during
             the study period

          6. Acute hepatitis in the 30 days prior to study entry

          7. Any gastrointestinal disease or surgical procedure that may impact the absorption of
             study drug

          8. Intractable diarrhea within 30 days prior to study entry

          9. Presence of a newly diagnosed Human immunodeficiency virus (HIV)-related opportunistic
             infection or any medical condition requiring acute therapy at the time of enrollment

         10. Subject's with Cushing's syndrome

         11. Untreated hypothyroidism or hyperthyroidism

         12. Recent therapy with agents with significant systemic myelosuppressive, neurotoxic,
             pancreatotoxic, hepatotoxic or cytotoxic potential within 3 months of study start

         13. Subject's with obstructive liver disease

         14. Active alcohol or illegal substance use

         15. Inability to swallow capsules

         16. Active peripheral neuropathy

         17. Presence of cardiomypathy or any significant cardiovascular disease

         18. Known, clinically significant cardiac conduction system disease

         19. Physical and Laboratory Test Findings:

               -  Moderate to severe hepatic insufficiency

               -  Screening laboratory values as follows:

                    -  T4 &lt; 4mcg/dL or &gt;11mcg/dL and/or Thyroid-stimulating hormone (TSH) &lt;0.5mU/L
                       or &gt;5.0mU/L

                    -  Calculated creatinine clearance &lt; 60 cc/min

                    -  Hemoglobin &lt; 8.0 g/dL

                    -  Total serum lipase ≥ 1.4 times the upper limit of normal (ULN)

                    -  Liver enzymes [Aspartate transaminase (AST), Alanine transaminase (ALT)] ≥ 5
                       times the ULN

                    -  Alkaline phosphatase &gt; 5 times the ULN

                    -  Platelets &lt; 50,000 cells/mm3

                    -  Positive blood screen for hepatitis B surface antigen (HBsAg)

                    -  Total serum bilirubin ≥ 1.5 times the ULN

         20. Allergies and Adverse Drug Reaction:

               -  Previously demonstrated hypersensitivity to any of the components of atazanavir
                  or the other experimental agents in this study

               -  Darunavir contains a sulfonamide moiety. Darunavir should be used with caution in
                  patients with a known sulfonamide allergy

               -  History of allergy to atazanavir, ritonavir, or darunavir

               -  History of allergy to NRTIs included as NRTI backbone options in this study

               -  History of clinically relevant severe drug reaction

         21. Sex and Reproductive Status:

               -  Women with a positive pregnancy test on enrollment prior to study drug
                  administration

               -  Women who become pregnant during the study will be taken off-protocol

               -  Women using a prohibited contraceptive method

               -  Women who are breastfeeding

         22. Other Exclusion Criteria

               -  Prisoners or subjects who are involuntarily incarcerated

               -  Subjects who are compulsorily detained for treatment of wither a psychiatric or
                  physical illness
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Southwest Center For Hiv/Aids</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health For Life Clinic Pllc</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uc Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metropolis Medical Pc</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Be Well Medical Center</name>
      <address>
        <city>Berkley</city>
        <state>Michigan</state>
        <zip>48072</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southampton Health Center</name>
      <address>
        <city>St Louis</city>
        <state>Missouri</state>
        <zip>63139</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>I.D. Care Associates</name>
      <address>
        <city>Hillsborourgh</city>
        <state>New Jersey</state>
        <zip>08844</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Michael'S Medical Center</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>James J Peters VAMC</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10468</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Infectious Disease Clinic &amp; AI</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link: http://www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 22, 2012</study_first_submitted>
  <study_first_submitted_qc>May 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 24, 2012</study_first_posted>
  <last_update_submitted>December 3, 2012</last_update_submitted>
  <last_update_submitted_qc>December 3, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 4, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Darunavir</mesh_term>
    <mesh_term>Atazanavir Sulfate</mesh_term>
    <mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

